← Leaderboards
Elizabeth Oelsner
Columbia University Health Sciences
$8,015,868
Attributed
$8,464,805
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2015–25$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,464,805 · 7
By mechanism
R01$6,200,482 · 2
R21$1,337,875 · 3
K23$686,448 · 1
R03$240,000 · 1
Top collaborators
- Pallavi P Balte2 shared
- Tiffany Renee Sanchez2 shared
Most similar at Columbia University Health Sciences
Same institution · by research overlap
- R Graham Barr$40,525,821
- Tiffany Renee Sanchez$222,750
- Lori J Mosca$5,505,916
- Alan J Moskowitz$38,974,795
Others in their field
Top investigators on “Hospitalization”
- Larry Arthur$288,323,000
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$230,275,254
- Judith S. Currier · University Of California Los Angeles$223,149,861
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$221,207,102
- Lawrence Corey · Fred Hutchinson Cancer Center$217,829,567
- Daniel R Kuritzkes · Brigham And Women'S Hospital$179,610,394
Research focus
HospitalizationAdultPulmonary EmphysemaGeneral PopulationLungParticipantPublic HealthInnovationFollow-UpAcuteSpirometrySamplingCohortMeasurementImageSmokerMortalityBlood FlowEndothelial DysfunctionBlood VesselsRisk FactorsPersonsEndotheliumPerfusion
Grant awards (21)
Metal Exposure and Subclinical Lung Disease in Adult E-cigarette Users$641,435
R01 · FY2025 · HL · contact PI
COVID-19 Lung Microvascular and Parenchymal Sequelae (Lung-MaPS)$657,696
R01 · FY2024 · HL · contact PI
Metal Exposure and Subclinical Lung Disease in Adult E-cigarette Users$642,080
R01 · FY2024 · HL · contact PI
Metal Exposure and Subclinical Lung Disease in Adult E-cigarette Users$692,819
R01 · FY2023 · HL · contact PI
COVID-19 Lung Microvascular and Parenchymal Sequelae (Lung-MaPS)$691,177
R01 · FY2023 · HL · contact PI
Changes in the public health burden of tobacco use during the COVID-19 pandemic: the C4R Study$205,625
R21 · FY2023 · HL
COVID-19 Lung Microvascular and Parenchymal Sequelae (Lung-MaPS)$707,532
R01 · FY2022 · HL · contact PI
Metal Exposure and Subclinical Lung Disease in Adult E-cigarette Users$703,641
R01 · FY2022 · HL · contact PI
Changes in the public health burden of tobacco use during the COVID-19 pandemic: the C4R Study$246,750
R21 · FY2022 · HL
COVID-19 Lung Microvascular and Parenchymal Sequelae (Lung-MaPS)$734,821
R01 · FY2021 · HL · contact PI
Metal Exposure and Subclinical Lung Disease in Adult E-cigarette Users$729,281
R01 · FY2021 · HL · contact PI
Respiratory health and cigar and pipe use in the NHLBI Pooled Cohorts Study$202,500
R21 · FY2021 · HL · contact PI
Respiratory health and cigar and pipe use in the NHLBI Pooled Cohorts Study$243,000
R21 · FY2020 · HL · contact PI
Hypercoagulability and Chronic Lung Disease in Older Adults$171,612
K23 · FY2019 · HL · contact PI
Hypercoagulability and Chronic Lung Disease in Older Adults$171,612
K23 · FY2018 · HL · contact PI
Hypercoagulability and Chronic Lung Disease in Older Adults$171,612
K23 · FY2017 · HL · contact PI
Ventilation and Pulmonary Endothelium Toxicities (VaPE-Tox) of E-cigarettes: A Randomized Crossover Pilot Study$120,000
R03 · FY2017 · HL · contact PI
Albuminuria and incident chronic lung disease exacerbations in five population-based cohorts$240,000
R21 · FY2016 · HL · contact PI
Hypercoagulability and Chronic Lung Disease in Older Adults$171,612
K23 · FY2016 · HL · contact PI
Ventilation and Pulmonary Endothelium Toxicities (VaPE-Tox) of E-cigarettes: A Randomized Crossover Pilot Study$120,000
R03 · FY2016 · HL · contact PI
Albuminuria and incident chronic lung disease exacerbations in five population-based cohorts$200,000
R21 · FY2015 · HL · contact PI